^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ECP-1014

    i
    Other names: ECP-1014, GIBH-1014
    Associations

    News

    Trials
    Company:
    Euclises Pharma
    Drug class:
    COX2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost3years
    ECP-1014 Treatment for Patients With Solid Tumor Cancers (clinicaltrials.gov)
    P1, N=29, Recruiting, Euclises Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Sep 2023
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
    |
    PTGS2 expression
    |
    ECP-1014